NCT00243100View on ClinicalTrials.gov

Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

August 31, 2011

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

vorinostat

Given orally

DRUG

gemcitabine hydrochloride

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00243100 - Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors | Biotech Hunter | Biotech Hunter